MIKA GRASSO RESIGNS FROM NUWELLIS INC, citing DISAGREEMENTS AND CLAIMED LACK OF TIMELY INFORMATION - SEC FILING
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NUWE?
Source: moomoo
Disagreements and Allegations: The article discusses disagreements and allegations surrounding the actions of Nuwellis Inc. and its CEO, Mika Grassore, particularly focusing on issues related to timely information sharing.
SEC Filing: It highlights the company's recent SEC filing, which addresses these disagreements and the implications of the alleged lack of timely information provided to stakeholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUWE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 1.050
Low
5.50
Averages
5.50
High
5.50
Current: 1.050
Low
5.50
Averages
5.50
High
5.50
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuwellis Pediatric Business Continues Growth Momentum
- Pediatric Business Growth: Nuwellis' pediatric category has become the largest and fastest-growing segment, accounting for approximately 50% of total U.S. revenue in 2025, marking a significant milestone that underscores the importance and versatility of Aquadex in pediatric patients.
- Market Expansion: The company's pediatric footprint has expanded to 47 centers nationwide, including six of the top 10 children's hospitals as ranked by U.S. News & World Report, enhancing institutional credibility and clinical rigor in hospital adoption.
- Precision Fluid Management Demand: The Aquadex therapy platform, cleared by the FDA for use in patients weighing 20kg and above, supports clinicians in managing fluid overload in critically ill children, reflecting the growing recognition of the need for precision fluid management in this vulnerable population.
- Strategic Growth Catalyst: Nuwellis expects continued pediatric expansion to remain a core component of its overall strategy, driving deeper engagement within specialty centers of excellence and expanding market access.
See More
MIKA GRASSO RESIGNS FROM NUWELLIS INC, citing DISAGREEMENTS AND CLAIMED LACK OF TIMELY INFORMATION - SEC FILING
Disagreements and Allegations: The article discusses disagreements and allegations surrounding the actions of Nuwellis Inc. and its CEO, Mika Grassore, particularly focusing on issues related to timely information sharing.
SEC Filing: It highlights the company's recent SEC filing, which addresses these disagreements and the implications of the alleged lack of timely information provided to stakeholders.
See More
Nuwellis Reports Q4 Earnings and Acquisition Plans
- Earnings Report: Nuwellis reported a Q4 GAAP EPS of -$1.50, with revenue of $2.42 million reflecting a 4.3% year-over-year increase, indicating ongoing financial challenges that may impact investor confidence.
- Acquisition Plans: The company announced its intention to acquire Rendiatech and raise $5 million through a private placement, a strategic move aimed at enhancing its technological capabilities and market competitiveness, although it may increase financial burdens in the short term.
- Market Performance: Following the earnings report, market reactions to Nuwellis' stock were lukewarm, especially when compared to strong buys in companies like Avino Silver & Gold and Harmony Gold, highlighting investor caution regarding its future outlook.
- Quant Rating: Seeking Alpha's Quant Rating indicates underperformance for Nuwellis, reflecting market concerns over its profitability and growth potential, which may lead investors to reassess their investment strategies.
See More
Nuwellis Set to Announce Q4 Earnings on March 10
- Earnings Announcement: Nuwellis is set to announce its Q4 earnings on March 10 before market open, with a consensus EPS estimate of -$1.56, reflecting a staggering 254.5% year-over-year decline, which could significantly impact investor confidence.
- Revenue Expectations: The anticipated revenue for Q4 is $2.31 million, showing a slight decrease of 0.4% year-over-year, indicating potential challenges in market competition that may affect future growth prospects.
- Historical Performance Review: Over the past year, Nuwellis has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, suggesting volatility in profitability and revenue growth that may lead to cautious investor sentiment regarding future performance.
- Financing Developments: Recently, Nuwellis raised $5 million through a private placement and plans to acquire Rendiatech, which could provide new growth opportunities but may also increase financial burdens, impacting short-term financial health.
See More
US Stocks Decline After Trump's Fed Chair Nomination
- Increased Market Volatility: Trump's nomination of former Fed official Warsh as the new Fed chair unsettled investors, leading to significant declines in major indices as market participants reacted to heightened uncertainty regarding future monetary policy.
- Gold and Silver Plunge: Following Warsh's nomination, gold and silver experienced their steepest declines in decades, prompting investors to reassess monetary policy risks and resulting in a substantial loss of confidence among precious metal investors.
- Corporate Earnings Impact: Microsoft saw its shares drop sharply despite reporting better-than-expected earnings, as concerns over slowing Azure growth and cautious guidance weighed heavily on investor sentiment, contrasting with Meta's stock rally driven by strong advertising and engagement metrics.
- Rising Treasury Yields: As expectations for a more hawkish Fed stance grew, Treasury yields edged higher while equities retreated, and commodities lost significant recent gains, reflecting a cautious outlook among investors regarding the economic landscape ahead.
See More
Nuwellis Appoints New CFO, Shares Drop 16.47%
- Executive Change: Nuwellis announced the appointment of Carisa Schultz as CFO, effective February 2, 2026, indicating a strategic shift in financial management that could impact future financial decisions and investor confidence.
- Stock Price Volatility: Following the announcement, Nuwellis shares dropped 16.47% in pre-market trading to $3.50, reflecting market uncertainty regarding the new CFO and potential implications for the company's future financial performance.
- Financial Background: Schultz most recently served as vice president of finance at NeueHealth, bringing extensive financial management experience that is expected to provide Nuwellis with new financial perspectives and strategic direction to enhance performance in the competitive healthcare sector.
- Performance Overview: Nuwellis' recent Q3 2025 earnings report showed a GAAP EPS of $0.56 and revenue of $2.22 million, and while the performance is decent, the executive change may negatively affect investor confidence and future earnings expectations.
See More
Nuwellis Pediatric Business Continues Growth Momentum
- Pediatric Business Growth: Nuwellis' pediatric category has become the largest and fastest-growing segment, accounting for approximately 50% of total U.S. revenue in 2025, marking a significant milestone that underscores the importance and versatility of Aquadex in pediatric patients.
- Market Expansion: The company's pediatric footprint has expanded to 47 centers nationwide, including six of the top 10 children's hospitals as ranked by U.S. News & World Report, enhancing institutional credibility and clinical rigor in hospital adoption.
- Precision Fluid Management Demand: The Aquadex therapy platform, cleared by the FDA for use in patients weighing 20kg and above, supports clinicians in managing fluid overload in critically ill children, reflecting the growing recognition of the need for precision fluid management in this vulnerable population.
- Strategic Growth Catalyst: Nuwellis expects continued pediatric expansion to remain a core component of its overall strategy, driving deeper engagement within specialty centers of excellence and expanding market access.
See More
MIKA GRASSO RESIGNS FROM NUWELLIS INC, citing DISAGREEMENTS AND CLAIMED LACK OF TIMELY INFORMATION - SEC FILING
Disagreements and Allegations: The article discusses disagreements and allegations surrounding the actions of Nuwellis Inc. and its CEO, Mika Grassore, particularly focusing on issues related to timely information sharing.
SEC Filing: It highlights the company's recent SEC filing, which addresses these disagreements and the implications of the alleged lack of timely information provided to stakeholders.
See More
Nuwellis Reports Q4 Earnings and Acquisition Plans
- Earnings Report: Nuwellis reported a Q4 GAAP EPS of -$1.50, with revenue of $2.42 million reflecting a 4.3% year-over-year increase, indicating ongoing financial challenges that may impact investor confidence.
- Acquisition Plans: The company announced its intention to acquire Rendiatech and raise $5 million through a private placement, a strategic move aimed at enhancing its technological capabilities and market competitiveness, although it may increase financial burdens in the short term.
- Market Performance: Following the earnings report, market reactions to Nuwellis' stock were lukewarm, especially when compared to strong buys in companies like Avino Silver & Gold and Harmony Gold, highlighting investor caution regarding its future outlook.
- Quant Rating: Seeking Alpha's Quant Rating indicates underperformance for Nuwellis, reflecting market concerns over its profitability and growth potential, which may lead investors to reassess their investment strategies.
See More
Nuwellis Set to Announce Q4 Earnings on March 10
- Earnings Announcement: Nuwellis is set to announce its Q4 earnings on March 10 before market open, with a consensus EPS estimate of -$1.56, reflecting a staggering 254.5% year-over-year decline, which could significantly impact investor confidence.
- Revenue Expectations: The anticipated revenue for Q4 is $2.31 million, showing a slight decrease of 0.4% year-over-year, indicating potential challenges in market competition that may affect future growth prospects.
- Historical Performance Review: Over the past year, Nuwellis has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, suggesting volatility in profitability and revenue growth that may lead to cautious investor sentiment regarding future performance.
- Financing Developments: Recently, Nuwellis raised $5 million through a private placement and plans to acquire Rendiatech, which could provide new growth opportunities but may also increase financial burdens, impacting short-term financial health.
See More
US Stocks Decline After Trump's Fed Chair Nomination
- Increased Market Volatility: Trump's nomination of former Fed official Warsh as the new Fed chair unsettled investors, leading to significant declines in major indices as market participants reacted to heightened uncertainty regarding future monetary policy.
- Gold and Silver Plunge: Following Warsh's nomination, gold and silver experienced their steepest declines in decades, prompting investors to reassess monetary policy risks and resulting in a substantial loss of confidence among precious metal investors.
- Corporate Earnings Impact: Microsoft saw its shares drop sharply despite reporting better-than-expected earnings, as concerns over slowing Azure growth and cautious guidance weighed heavily on investor sentiment, contrasting with Meta's stock rally driven by strong advertising and engagement metrics.
- Rising Treasury Yields: As expectations for a more hawkish Fed stance grew, Treasury yields edged higher while equities retreated, and commodities lost significant recent gains, reflecting a cautious outlook among investors regarding the economic landscape ahead.
See More
Nuwellis Appoints New CFO, Shares Drop 16.47%
- Executive Change: Nuwellis announced the appointment of Carisa Schultz as CFO, effective February 2, 2026, indicating a strategic shift in financial management that could impact future financial decisions and investor confidence.
- Stock Price Volatility: Following the announcement, Nuwellis shares dropped 16.47% in pre-market trading to $3.50, reflecting market uncertainty regarding the new CFO and potential implications for the company's future financial performance.
- Financial Background: Schultz most recently served as vice president of finance at NeueHealth, bringing extensive financial management experience that is expected to provide Nuwellis with new financial perspectives and strategic direction to enhance performance in the competitive healthcare sector.
- Performance Overview: Nuwellis' recent Q3 2025 earnings report showed a GAAP EPS of $0.56 and revenue of $2.22 million, and while the performance is decent, the executive change may negatively affect investor confidence and future earnings expectations.
See More
